ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,749,468 | -46.1% | 156,622 | +3.3% | 0.00% | 0.0% |
| Q2 2023 | $3,245,460 | -46.0% | 151,657 | +2.1% | 0.00% | -50.0% |
| Q1 2023 | $6,007,685 | -11.5% | 148,558 | +1.8% | 0.00% | 0.0% |
| Q4 2022 | $6,786,803 | -7.9% | 145,890 | +2.7% | 0.00% | -33.3% |
| Q3 2022 | $7,372,000 | +16.2% | 142,107 | +5.9% | 0.00% | +50.0% |
| Q2 2022 | $6,346,000 | -34.5% | 134,231 | -1.4% | 0.00% | -33.3% |
| Q1 2022 | $9,690,000 | +0.2% | 136,126 | +5.3% | 0.00% | 0.0% |
| Q4 2021 | $9,667,000 | +33.2% | 129,263 | +1.2% | 0.00% | +50.0% |
| Q3 2021 | $7,258,000 | +30.1% | 127,746 | +0.8% | 0.00% | 0.0% |
| Q2 2021 | $5,578,000 | -9.3% | 126,731 | +1.7% | 0.00% | 0.0% |
| Q1 2021 | $6,148,000 | +21.0% | 124,640 | +3.2% | 0.00% | 0.0% |
| Q4 2020 | $5,083,000 | -5.9% | 120,732 | +2.4% | 0.00% | 0.0% |
| Q3 2020 | $5,399,000 | -6.4% | 117,930 | +2.7% | 0.00% | -33.3% |
| Q2 2020 | $5,767,000 | +4.3% | 114,856 | +6.8% | 0.00% | 0.0% |
| Q1 2020 | $5,531,000 | -17.9% | 107,540 | -1.4% | 0.00% | -25.0% |
| Q4 2019 | $6,736,000 | +2.9% | 109,019 | +0.0% | 0.00% | 0.0% |
| Q3 2019 | $6,547,000 | -26.9% | 108,967 | +2.7% | 0.00% | -20.0% |
| Q2 2019 | $8,957,000 | -7.3% | 106,141 | +4.9% | 0.01% | -16.7% |
| Q1 2019 | $9,666,000 | +40.1% | 101,191 | +3.9% | 0.01% | +20.0% |
| Q4 2018 | $6,898,000 | -22.8% | 97,377 | -6.9% | 0.01% | -16.7% |
| Q3 2018 | $8,936,000 | -18.3% | 104,559 | +10.8% | 0.01% | -25.0% |
| Q2 2018 | $10,933,000 | +47.7% | 94,329 | +3.1% | 0.01% | +33.3% |
| Q1 2018 | $7,403,000 | +29.7% | 91,494 | -5.9% | 0.01% | +20.0% |
| Q4 2017 | $5,708,000 | +116.1% | 97,272 | +72.4% | 0.01% | +150.0% |
| Q3 2017 | $2,641,000 | +36.8% | 56,419 | +5.2% | 0.00% | 0.0% |
| Q2 2017 | $1,930,000 | +17.5% | 53,616 | +0.6% | 0.00% | 0.0% |
| Q1 2017 | $1,643,000 | -3.1% | 53,312 | +5.4% | 0.00% | 0.0% |
| Q4 2016 | $1,695,000 | +32.3% | 50,576 | +5.1% | 0.00% | 0.0% |
| Q3 2016 | $1,281,000 | +10.1% | 48,112 | -8.8% | 0.00% | +100.0% |
| Q2 2016 | $1,164,000 | -68.5% | 52,762 | -58.1% | 0.00% | -80.0% |
| Q1 2016 | $3,698,000 | -34.2% | 125,888 | -26.0% | 0.01% | -37.5% |
| Q4 2015 | $5,619,000 | -5.6% | 170,153 | +3.3% | 0.01% | -11.1% |
| Q3 2015 | $5,951,000 | +10.3% | 164,640 | +37.3% | 0.01% | +28.6% |
| Q2 2015 | $5,396,000 | +135.8% | 119,924 | +60.5% | 0.01% | +133.3% |
| Q1 2015 | $2,288,000 | -36.5% | 74,696 | +5.5% | 0.00% | -40.0% |
| Q4 2014 | $3,602,000 | +66.0% | 70,822 | +29.2% | 0.01% | +25.0% |
| Q3 2014 | $2,170,000 | +185.2% | 54,834 | +210.6% | 0.00% | +300.0% |
| Q2 2014 | $761,000 | +143.1% | 17,654 | +126.3% | 0.00% | 0.0% |
| Q1 2014 | $313,000 | +50.5% | 7,802 | +2.4% | 0.00% | – |
| Q4 2013 | $208,000 | -48.1% | 7,622 | -54.9% | 0.00% | -100.0% |
| Q3 2013 | $401,000 | – | 16,906 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |